TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06430385: ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2

Sponsor: Ionis Pharmaceuticals, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 48 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,382,780

Rescue Site Savings

+$903,040

Unlock Full NCT06430385 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06430385 Rescue Dossier →